Scottish Regulators Approve Forxiga for the NHS

Patients with diabetes in Scotland have gained routine access to AstraZeneca/ Bristol-Myers Squibb’s Forxiga on the UK National Health Service (NHS) after it was considered cost-effective by the Scottish Medicines Consortium (SMC). The SMC have dispensed guidance to healthcare professionals approving the use of the first-in-class drug Forxiga (dapagliflozin) in adults with type 2 diabetes

Continue Reading

MedImmune Partners with Wuxi AppTec

AstraZeneca have reinforced their interest in China by entering into a joint venture between their biotechnology arm MedImmune, and Chinese firm WuXi AppTec, which seeks to quicken the development of a new medicine for inflammatory conditions in the country. Under the joint venture, in which the two organisations will have equal ownership, MedImmune’s experimental, fully-human

Continue Reading

Bristol-Myers Squibb Completes Amylin Purchase

Bristol-Myers Squibb (B-MS) yesterday announced that they have completed their $5 billion purchase of Amylin and its diabetes franchise, meaning they can now progress onto a planned marketing alliance with drug giant AstraZeneca. The New York-based drug maker, who agreed to buy Amylin on the 1st July, confirmed that they have now successfully finalised their

Continue Reading

US Judge Backs AstraZeneca’s Seroquel XR patent

AstraZeneca announced earlier today that a US district court has ruled that the formulation patent for its extended-release version of the antipsychotic blockbuster, Seroquel XR, is valid and has been infringed by generics companies. The court in New Jersey found the formulation patent protecting Seroquel XR (quetiapine fumarate) extended-release tablets to be valid and ruled

Continue Reading

AstraZeneca Appoints Johansson as Chairman

AstraZeneca announced yesterday that they have appointed Swedish executive Leif Johansson from telecoms group Ericsson as chairman. Leif Johansson will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 26 April 2012, with the aim that he will take over completely from Louis Schweitzer on the 1

Continue Reading